Packaging: Blister of 10 tablets. Box of 5 blisters.
Compostion: Meloxicam 7.5mg
Meloxicam is used in the management of rheumatoid arthritis, for the short-term symptomatic treatment of acute exacerbations of osteoarthritis, and for the symptomatic treatment of ankylosing spondylitis. It may also be used in the treatment of juvenile idiopathic arthritis.
Known hypersensitivity to meloxicam or any ingredient in the formulation.
History of urticaria, angioedema, bronchospasm, severe rhinitis, or shock precipitated by aspirin or other NSAIDs.
History of aspirin sensitivity, asthma, and nasal polyps
GI effects: Risk of serious GI effects (e.g., bleeding, ulceration, perforation), which can occur at any time with or without warning signs or symptoms. Concomitant therapies that may increase risk include a history of GI bleeding or ulceration, longer duration of NSAIDs therapy, treatment with anticoagulants or oral corticosteroids, smoking, alcohol dependence, poor general health, or older age (higher risk of fatal GI complications).
Hypertension: Use of NSAIDs, including meloxicam, can result in the onset of hypertension or worsening of preexisting hypertension; either of these occurrences may contribute to the increased incidence of cardiovascular events.
Renal effects: Renal papillary necrosis or other renal medullary changes may occur with long-term administration of NSAIDs.
Sensitivity reactions: Sensitivity reactions, including anaphylactoid reactions, possible in patients without prior exposure to meloxicam.
Serious skin reactions (e.g., exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis) can occur in patients receiving meloxicam.
Hematologic effects: Anemia has been reported, principally in patients receiving long-term (6 months’duration) therapy with meloxicam.
Meloxicam STADA® 7.5 mg is orally administered.
Rheumatoid arthritis and ankylosing spondylitis: a usual dose of 15 mg daily as a single dose. Those with an increased risk of adverse reactions should be started on 7.5 mg daily. A dose of 7.5 mg daily in recommended for long-term treatment in the elderly.
Acute exacerbations of osteoarthritis: the usual daily dose of meloxicam is 7.5 mg, increased if necessary to a maximum of 15 mg daily given as a single dose.
Juvenile idiopathic arthritis in children aged 2 years and over: 125 micrograms/kg once daily, up to a maximum of 7.5 mg daily.
According to body-weight, in those aged 12 to 18 years who are intolerant of other NSAIDs:
Less than 50 kg, 7.5 mg once daily.
Over 50 kg, 15 mg once daily.
Administration in renal impairment:
Meloxicam is normally contraindicated in patients with severe renal impairment. However, in dialysed patients, meloxicam may be given in a dose of 7.5 mg daily.
Shelf - Life:
36 months from the date of manufacturing.